Article info

Download PDFPDF
Mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) chemotherapy for gynecological sarcomas

Authors

  • M. L. Pearl Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Medicine, State University of New York at Stony Brook, Stony Brook, New York PubMed articlesGoogle scholar articles
  • M. Inagami Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Medicine, State University of New York at Stony Brook, Stony Brook, New York PubMed articlesGoogle scholar articles
  • D. L. Mccauley Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Medicine, State University of New York at Stony Brook, Stony Brook, New York PubMed articlesGoogle scholar articles
  • F. A. Valea Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Medicine, State University of New York at Stony Brook, Stony Brook, New York PubMed articlesGoogle scholar articles
  • E. Chalas Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Medicine, State University of New York at Stony Brook, Stony Brook, New York PubMed articlesGoogle scholar articles
  • M. Fischer Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Medicine, State University of New York at Stony Brook, Stony Brook, New York PubMed articlesGoogle scholar articles
  1. Address correspondence and reprint requests to: Michael L. Pearl, MD, Long Island Gynecologic Oncologists, PC, 994 Jericho Turnpike, Smithtown, New York 11787. Email: mlpearl{at}notes.cc.sunysb.edu.

Citation

Pearl ML, Inagami M, Mccauley DL, et al
Mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) chemotherapy for gynecological sarcomas

Publication history

  • First published October 1, 2002.
Online issue publication 
March 06, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.